Journal article
Psychomotor depressive symptoms may differentially respond to venlafaxine
AB Singh, CA Bousman, CH Ng, K Byron, M Berk
International Clinical Psychopharmacology | LIPPINCOTT WILLIAMS & WILKINS | Published : 2013
Abstract
Predicting differential antidepressant efficacy remains an elusive goal in major depressive disorder (MDD). The aims of this study were three-fold. Firstly, to examine if psychomotor retardation symptoms (item 8 on the 17-item Hamilton Depression Rating Scale) improve preferentially to venlafaxine (VEN) over escitalopram (ESC) treatment. Secondly, whether the 18 item CORE psychomotor signs scale predicted antidepressant remission. Finally, to investigate the role of two norepinephrine transporter gene (NET) polymorphisms (rs2242446 and rs5569) on antidepressant efficacy. Adults with Diagnostic and Statistical Manual of Mental Disorders, 4th ed. MDD (n=113) were treated with ESC or VEN prospe..
View full abstractGrants
Funding Acknowledgements
Ajeet B. Singh wishes to acknowledge a young investigator grant awarded by The Royal Australian and New Zealand College of Psychiatrists, Healthscope Molecular for providing the genotyping, and Dr Cameron Osborne for statistical assistance.